title: [Use of protein C concentrate in adult patients with severe sepsis and septic shock].
abstract: OBJECTIVE
  The aim of this study is to describe the first experiences on the use of protein C concentrate (PC) in adult patients with severe sepsis and septic shock and clinical contraindications to activated protein C (APC). On the basis of the effectiveness demonstrated by the activated form in sepsis and of the encouraging results expressed in literature of protein C concentrate (PC) mainly about meningococcus fulminating infections, we carried out an observational study on protein C concentrate (PC) with 28-day follow-up and a daily analysis of the hemato-chemical and clinical parameters. Particular attention was paid to the variations in the PC plasma levels, to the modifications of the coagulation system, to the SOFA score as well as to the safety under bleeding risk conditions.
  
  
  METHODS
  The study included 7 patients (5 females and 2 males) either with severe sepsis (2). or septic shock (5); one of them had DIC, with PC plasma levels less than 50%. APC could not be administered because of clinical reasons. Patients' mean age was 60.5 years (43-78), the average SAPS II 52.2 (36-72), the pathologies leading to sepsis were lung infections (3). and peritonitis (4). The average time elapsed between the onset of the organ failure and the beginning of treatment with PC was 27.7 hours (12-42).
  
  
  RESULTS
  Mortality on day 28 was 42.8% (3 deaths), in all patients the PC plasma levels were brought again to the physiological values. Among the biochemical parameters recorded during the PC infusion, was observed in particular a significant decrease of PDFs, a general rise of the platelet count, and a reduction of the lactic acid levels. No adverse reaction or bleeding complication were seen, even if most of the patients' coagulation was altered or at risk due to neurological problems or repeated surgery.
  
  
  CONCLUSIONS
  In our small number of patients, protein C concentrate has proven to be safe and particularly useful in the control of the coagulopathy triggered and sustained by sepsis.
authors.affiliation: Dipartimento di Farmacologia e Anestesiologia, Sezione Anestesiologia e Rianimazione, Università degli Studi di Padova, Padova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Baratto
authors.forename: F
authors.initials: F
authors.lastname: Michielan
authors.forename: G
authors.initials: G
authors.lastname: Gagliardi
authors.forename: G
authors.initials: G
authors.lastname: Di Gregorio
authors.forename: A
authors.initials: A
authors.lastname: Pasqualetto
authors.forename: M
authors.initials: M
authors.lastname: Meroni
authors.forename: G P
authors.initials: GP
authors.lastname: Giron
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D020151:Protein C Deficiency / Q000150:complications / Q000188:drug therapy; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy*
chemical_list: D011486:Protein C